PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Meta-analysis of 18 RCTs showed a reduction in cardiovascular events (RR: 0.35) [PMID:28634988]
Saponins exhibit anti-inflammatory activity, reduce oxidative stress, protect mitochondria, and repair the blood-brain barrier [PMID:32907361]
Experimental evidence suggests potential in alleviating cytokine storms and improving post-COVID-19 symptoms [PMID:37362082]
Saponins reduced inflammatory injury and collagen deposition by suppressing the PI3K/AKT pathway to enhance autophagy and apoptosis in mice [PMID:41309997]
Saponins alleviate colitis by regulating the Th17/Treg balance via gut microbiota and bile acid metabolism [PMID:40165428]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 37946257 (2023) — Panax notoginseng: derived exosome-like nanoparticles attenuate ischemia reperfusion injury via altering microglia polarization. · Journal of nanobiotechnology
- 2.PMID: 42034027 (2026) — Panax notoginseng saponins enhance osteogenesis-angiogenesis coupling to ameliorate osteoporosis combined with intervertebral disc degeneration. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 3.PMID: 37362082 (2023) — The potential of Panax notoginseng against COVID-19 infection. · Journal of ginseng research
- 4.PMID: 32907361 (2020) — Panax notoginseng for Cerebral Ischemia: A Systematic Review. · The American journal of Chinese medicine
- 5.PMID: 38719196 (2024)